Thank you for visiting www.solx.com. If you searched for this web site because of an interest in the treatment of glaucoma, we hope you will find the information contained on our site to be valuable.
Advances in the surgical treatment of glaucoma have the potential to change the way patients with glaucoma are treated. SOLX® provides a powerful new set of tools that have the potential to change the way primary open-angle glaucoma is treated. The SOLX Glaucoma Treatment System is the first multiple approach platform of technologies designed to lower intraocular pressure (IOP) without a bleb, thereby reducing or eliminating bleb-related complications and the need for multiple medications. The Glaucoma Treatment System is comprised of the SOLX® Gold Shunt implant, the SOLX® 790 Laser for trabeculoplasty and the SOLX IOP Sensor, a device designed to continuously monitor IOP. These devices are designed to work individually or as a combination therapy.
SOLX commenced commercial operations in 2000 and spent the following four years in research and product development at Boston University’s Photonics Center Business Acceleration Program.
SOLX Milestones:
| June 2004: SOLX begins enrolling patients in a US laser trial that includes 180 eyes with one-year follow-up. The results will be used to support an FDA 510(k) submission in 2008. February 2005: SOLX holds its first surgical training session in Madrid, Spain for its Gold Shunt. This symposium was led by Gabriel Simon, MD, PhD, director of ophthalmic research at the Boston University Photonics Center. As of January, 2008, the Gold Shunt has successfully been implanted in more than 500 patients outside of the United States. October 2005: SOLX is granted CE approval for the Gold Shunt and 790 Laser by the European authority’s notified body Intertek/Amtac. Both become available for sale outside the US. December 2005: SOLX begins enrollment for the Gold Shunt FDA clinical trial. The study includes 180 eyes with one-year follow-up. September 2006: Ontario, Canada-based OccuLogix, seeking to build a leading ophthalmic device company focused on age-related eye diseases, acquires SOLX. SOLX becomes OccuLogix' glaucoma division and continues to commercialize the SOLX Glaucoma Treatment System. November 2006: SOLX announces its international training and certification program for the Gold Shunt for ophthalmologists in Europe and the Middle East, with additional instructive training sessions being offered internationally. In Europe, more than 100 ophthalmic surgeons have been trained on the procedure. |
Features of the SOLX Glaucoma Treatment System:
- The Gold Shunt is the only shunt designed to reduce elevated IOP in the eye by connecting the anterior chamber and suprachoroidal space.
- The 790 Laser penetrates deeper than lasers currently used in trabeculoplasty, and may lead to longer-lasting treatment benefits.
- Both the 790 Laser and the Gold Shunt provide physicians with a new level of control in the treatment of glaucoma.
- Both are consistent with treatment methods that are already familiar to physicians.
- Both are capable of reducing side effects and costs associated with using multiple medications.
SYSTEM COMPONENTS
The SOLX Gold Shunt
The SOLX Gold Shunt is a sterile, multi-channeled, valveless, flat drainage device designed for implantation between the anterior chamber and suprachoroidal space of the eye. The ultra-thin implant is fabricated from biocompatible 24 karat 99.95% gold, and has a number of small channels that directs significant aqueous flow to the suprachoroidal space.
The SOLX 790 Laser
The SOLX 790 Laser is a solid-state Titanium:Sapphire Laser that performs Laser Trabeculoplasty, a glaucoma treatment used to lower the intraocular pressure of the eye. Its near-infrared 790nm wavelength penetrates deeply into the tissues of the Trabecular Meshwork without causing significant amounts of thermal, coagulative, or biodestructive damage unlike other ophthalmic laser platforms.
The SOLX IOP Sensor
The SOLX IOP Sensor is an implantable sensor designed for continuous monitoring of IOP. The device was prototyped at Purdue Brain-Computer Interface (BCI) Lab. The device is expected to enter human clinical trials in the US in 2009.
CONTACT
For more information, please contact Doug Adams, at 781-547-4051 or doug@solx.com or visit SOLX online at www.solx.com.
Learn More About SOLX:
It is advised that you have the Flash plug in for optimal viewing experience.